3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Thoracic
2
Genitourinary
2
Tumor-Agnostic
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Temozolomide
610
Radiotherapy
388
Bevacizumab
254
Magnetic Resonance Spectroscopy
203
Cyclophosphamide
177
Carboplatin
159
Radiosurgery
146
Etoposide
132
Radiation
121
Irinotecan
115
Vincristine
114
Cisplatin
102
Filgrastim
100
Specimen Handling
88
Nivolumab
87
pembrolizumab
82
Lomustine
81
Topotecan
73
Surgical Procedures, Operative
73
Doxorubicin
60
Melphalan
59
Carmustine
57
sargramostim
53
Radiotherapy, Intensity-Modulated
53
Isotretinoin
53
Peripheral Blood Stem Cell Transplantation
52
Granulocyte Colony-Stimulating Factor
50
Erlotinib Hydrochloride
50
Everolimus
48
Chemotherapy, Adjuvant
48
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
cabiralizumab
×
CNS
×
Clear all
NCT02526017
2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1
Completed
313 enrolled
30 charts